UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): August 31, 2023 |
FIBROGEN, INC.
(Exact name of Registrant as Specified in Its Charter)
| | | | |
Delaware | 001-36740 | 77-0357827 |
(State or Other Jurisdiction
of Incorporation) | (Commission File Number) | (IRS Employer
Identification No.) |
| | | | |
409 Illinois Street | |
San Francisco, California | | 94158 |
(Address of Principal Executive Offices) | | (Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 415 978-1200 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class
| | Trading
Symbol(s) | |
Name of each exchange on which registered
|
Common Stock, $0.01 par value | | FGEN | | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 31, 2023, Mark Eisner, M.D. resigned from his position as Chief Medical Officer of FibroGen, Inc. (the “Company”), effective September 8, 2023, to pursue other opportunities. Dr. Eisner will continue as an employee through the effective date of his resignation, after which time, he will serve the Company as a consultant under a consulting agreement (the “Consulting Agreement”) to provide transition services. Dr. Eisner’s resignation is voluntary and is not the result of any disagreement with the Company. The Company has commenced a search for a new Chief Medical Officer. The Company would like to thank Dr. Eisner for his service and for the many contributions he made as Chief Medical Officer and as a member of the executive team.
Under the Consulting Agreement, Dr. Eisner will receive $15,000 per month and his stock awards will continue to vest in accordance with the existing terms applicable to such awards. The Consulting Agreement will continue until October 11, 2023, and may be extended by mutual agreement. The preceding summary of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreement which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | | FIBROGEN, INC. |
| | | |
Date: | September 6, 2023 | By: | /s/ Michael Lowenstein |
| | | Michael Lowenstein
Chief Legal Officer |
